Hypercalcemia is a medical condition which involves elevation of calcium level in the blood. Surplus calcium levels in your blood can create kidney stones, obstruct the way your heart and brain functions and weaken your bones. Hypercalcemia is commonly result of hyperactive parathyroid glands. Hypercalcemia is generally accompanied by several symptoms like feeling sick, tiredness, vomiting, bone pains and kidney stones. Hypercalcemia is the most common metabolic disorder related with neoplastic diseases. It has estimated that hypercalcemia occurs in about 10% to 20% of all patients with cancer. Hypercalcemia is caused due to excessive release of calcium in the skeletal system and due to increased intestinal calcium absorption in the body. Hypercalcemia treatment focuses on lowering the serum calcium concentration in the body. Some of the non – pharmacological therapies used in the treatment of hypercalcemia are as mobilization, saline diuresis and volume expansion, Inhibition of bone resorption, reduction of gastrointestinal calcium absorption and dialysis.
Hypercalcemia Treatment Market: Drivers and Restraints
Presently, the global hypercalcemia treatment market is an attractive market, and is primarily driven by the high adoption rate of novel therapies. Moreover, factor such as increased government support for developing effective medications for rare disease such as hypercalcemia is expected to drive the growth of this market. However, factors such as high cost of therapy and stringent drug regulatory policies might impede the growth of the market.
Request free sample Report: http://www.futuremarketinsights.com/reports/sample/rep-gb-1320
Hypercalcemia Treatment Market: Segmentation
Hypercalcemia Treatment market is classified on the basis of drug type, indication, end user and geography.
Based on the drug therapies type, the global hypercalcemia Treatment market is segmented into the following:
- Antidote or Hypercalcemia Agents
- Calcimimetic Agent
- Antineoplastic drugs
Based on the indications, the global hypercalcemia Treatment market is segmented into the following:
- Primary Hyperparathyroidism
- Secondary Hyperparathyroidism
- Tertiary Hyperparathyroidism
- Humoral Hypercalcemia of Malignancy
- Other (Thyrotoxicosis, Immobilization etc.)
Based on the type end user, the global hypercalcemia Treatment market is segmented into the following:
- Hospitals Clinics
- Private Clinics
- Retail Pharmacies and Drug Stores
Hypercalcemia Treatment Market: Overview
The primary hyperparathyroidism and humoral hypercalcemia of malignancy type is expected to dominate the global hypercalcemia market over the forecast period as they account for 90% of the hypercalcemia cases. Growing incidence of hypercalcemia, increasing awareness among the people and developments in new advance treatment are some other factors which are expected to support the growth of global hyperparathyroidism market over the forecast period.
Request for TOC: http://www.futuremarketinsights.com/toc/rep-gb-1320
Hypercalcemia Treatment Market: Region-wise Outlook
Depending on geographic regions, global hypercalcemia market is segmented into seven key regions: North America, Latin America, Eastern Europe, Western Europe, Asia Pacific Excluding Japan, Japan and Middle East & Africa. In terms of geography, North America is the leading market owing to the high incidence rate of hypercalcemia in the U.S. various research studies suggests that the incidence of hypercalcemia in the U.S. is almost 1 to 2 cases per 1000 adults. However, other regions such as Latin America, MEA and APAC are estimated to witness sluggish growth due to the high costs of these therapies and low awareness among population.
Hypercalcemia Treatment Market: Key Players
The companies involved in the development and commercialization of hypercalcemia treatment products are Cipla Inc., Sun Pharmaceutical Industries Ltd., Amgen Inc., Genta Inc., Par Pharmaceutical Companies, Inc., Novartis International AG Pfizer Inc. and others.
Browse full report: http://www.futuremarketinsights.com/reports/hypercalcemia-treatment-market